Asset profile
HLX04-O
Monoclonal antibody
Evidence outlook · lead readout
NCT04740671 · Age Related Macular Degeneration
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT04740671: The trial randomized 410 participants to HLX04-O or the active comparator ranibizumab and masked both participants and investigators. Its primary clinical endpoint was the mean change in best-corrected visual acuity at Week 36, but no statistical comparison or outcome result is available yet.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
42 competitors in this universe: 11 direct rivals (same mechanism and indication), 11 same-class, 20 same-indication; 18 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| HLX04-O: this drug | Phase 3 | Monoclonal antibody | VEGF-A | ||
| Aflibercept (Eylea) | Approved | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | ||
| Brolucizumab-Dbll | Approved | Monoclonal antibody | VEGF-A | ||
| Pegaptanib (Macugen) | Approved | Small molecule | VEGF-A | ||
| Ranibizumab (Lucentis) | Approved | Monoclonal antibody | VEGF-A | ||
| ABBV-RGX-314 | Phase 3 | Gene therapy / editing | VEGF-A | ||
| CKD-701 | Phase 3 | Monoclonal antibody | VEGF-A | ||
| KSI-301 | Phase 3 | Monoclonal antibody | VEGF-A | ||
| RGX-314 | Phase 3 | Gene therapy / editing | VEGF-A | ||
| Surabgene Lomparvovec (ABBV-RGX-314) | Phase 3 | Gene therapy / editing | VEGF-A | ||
| Tarcocimab Tedromer | Phase 3 | Monoclonal antibody | VEGF-A | ||
| MW02 | Phase 2/3 | Monoclonal antibody | VEGF-A | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A |
…and 27 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.